What is CoImmune?
CoImmune is a privately held, clinical stage immuno-oncology company dedicated to redefining cancer treatment through advanced cellular immunotherapies. The company's proprietary allogeneic CAR-CIK technology platform is designed for both liquid and solid tumors, offering a potential enhancement over traditional CAR-T therapy by promising increased efficacy while substantially reducing toxicity. Furthermore, CoImmune is developing autologous RNA-loaded dendritic cell technology for solid tumors, which utilizes amplified total tumor mRNA to program highly engineered dendritic cells. This approach aims to generate robust immune responses against neoantigens without the necessity of identifying them individually, marking a significant stride in personalized cancer care.
How much funding has CoImmune raised?
CoImmune has raised a total of $45M across 1 funding round:
Series A
$45M
Series A (2020): $45M with participation from Dr. Lucio Rovati
What's next for CoImmune?
The recent major strategic investment provides CoImmune with substantial backing to advance its clinical pipeline and further develop its innovative cellular immunotherapies. This capital infusion is expected to accelerate the progression of its CAR-CIK and dendritic cell technologies through clinical trials, potentially bringing novel treatment options to patients with solid and liquid tumors. The company's focus on reducing toxicity while enhancing efficacy positions it as a key player in the evolving landscape of immuno-oncology, with future developments likely centered on expanding its therapeutic applications and securing further strategic partnerships to drive commercialization.
See full CoImmune company page
